TG Therapeutics
is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.
Product Pipeline
Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.
TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.
For Investors
Stock Quote at: Apr 23, 4:00PM EDT
News & Events
4.7.14
TG Therapeutics, Inc. Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014
3.11.14
Quick Links
